Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Sponsor: Tango Therapeutics, Inc.
Terminated
Sponsor Decision - Business Decisions
Other terminated trials from Tango Therapeutics, Inc.
More terminations from Tango Therapeutics, Inc.
Other Locally Advanced Solid Tumor trials with similar outcome
Listed as NCT05275478, this observational or N/A phase trial focuses on Locally Advanced Solid Tumor and remains terminated or withdrawn. Sponsored by Tango Therapeutics, Inc., it has been updated 22 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)This is a Phase 1/2 multi-center, open label study in solid tumor patients (including glioblastoma) who have a confirmed homozygous MTAP deletion in their tumor. The Phase 1 portion is a dose escalation study of oral TNG908 in patients with confirmed MTAP-deleted solid tumors. In Phase 2, 6 expansion arms defined by confirmed MTAP-deleted tumor types will enroll in parallel at the RP2D of TNG908. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.
This is a Phase 1/2 multi-center, open label study in solid tumor patients (including glioblastoma) who have a confirmed homozygous MTAP deletion in their tumor. The Phase 1 portion is a dose escalation study of oral TNG908 in patients with confirmed MTAP-deleted solid tumors. In Phase 2, 6 expansion arms defined by confirmed MTAP-deleted tumor types will enroll in parallel at the RP2D of TNG908. In both parts of the study participants who tolerate the drug may continue treatment until disease progression.
Status Flow
Change History
22 versions recorded-
Apr 16, 2026 — Present [daily]
Terminated
Status: Active Not Recruiting → Terminated · Phase: PHASE1/PHASE2 → None
-
Dec 2025 — Apr 2026 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
▶ Show 17 earlier versions
-
Feb 2025 — May 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2024 — May 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Feb 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.
Contact Information
- Tango Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .